These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 14594435)

  • 21. Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Heidenreich PA; Davis BR; Cutler JA; Furberg CD; Lairson DR; Shlipak MG; Pressel SL; Nwachuku C; Goldman L
    J Gen Intern Med; 2008 May; 23(5):509-16. PubMed ID: 18228109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.
    Einhorn PT; Davis BR; Massie BM; Cushman WC; Piller LB; Simpson LM; Levy D; Nwachuku CE; Black HR;
    Am Heart J; 2007 Jan; 153(1):42-53. PubMed ID: 17174636
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ALLHAT Trial. Diuretics are still the preferred initial drugs for high blood pressure.
    Vidt DG
    Cleve Clin J Med; 2003 Mar; 70(3):263-9. PubMed ID: 12678218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Recent intervention studies with antihypertensive drugs and their influence on guidelines].
    Rahn KH
    Med Klin (Munich); 2003 Dec; 98(12):771-5. PubMed ID: 14685679
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).
    Dewland TA; Soliman EZ; Yamal JM; Davis BR; Alonso A; Albert CM; Simpson LM; Haywood LJ; Marcus GM
    Circ Arrhythm Electrophysiol; 2017 Dec; 10(12):. PubMed ID: 29212812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
    Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
    J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial choice of antihypertensive on long-term cardiovascular outcomes in CKD.
    Whaley-Connell A; Sowers JR
    Clin J Am Soc Nephrol; 2012 Jun; 7(6):884-6. PubMed ID: 22595830
    [No Abstract]   [Full Text] [Related]  

  • 28. Results of the ALLHAT trial: is the debate about initial antihypertensive drug therapy over?
    Moser M
    J Clin Hypertens (Greenwich); 2003; 5(1):5-8. PubMed ID: 12556646
    [No Abstract]   [Full Text] [Related]  

  • 29. ALLHAT: what has it taught us so far?
    Leenen FH
    CMAJ; 2004 Sep; 171(7):719-20. PubMed ID: 15451829
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber MA; Franklin S; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T;
    Ann Intern Med; 2006 Feb; 144(3):172-80. PubMed ID: 16461961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ALLHAT report: a case of information and misinformation.
    Weber MA
    J Clin Hypertens (Greenwich); 2003; 5(1):9-13. PubMed ID: 12556647
    [No Abstract]   [Full Text] [Related]  

  • 32. The putative link between glycemic control and cardiac arrhythmias.
    Varughese GI; Tahrani AA; Scarpello JH
    Arch Intern Med; 2007 Jul; 167(13):1433-4; author reply 1434-5. PubMed ID: 17620539
    [No Abstract]   [Full Text] [Related]  

  • 33. How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure?
    Proschan M; Ford CE; Cutler JA; Graumlich JF; Pavlik V; Cushman WC; Davis BR; Alderman MH; Gordon D; Furberg CD; Franklin SS; Blumenthal SS; Castaldo RS; Preston RA;
    Stat Med; 2013 Feb; 32(5):884-97. PubMed ID: 22961832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of antihypertensive class on gout in older adults: secondary analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Juraschek SP; Simpson LM; Davis BR; Shmerling RH; Beach JL; Ishak A; Mukamal KJ
    J Hypertens; 2020 May; 38(5):954-960. PubMed ID: 31977576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How effective is doxazosin compared with chlorthalidone in the treatment of hypertension?
    Koval PG; McDiarmid T
    J Fam Pract; 2000 Jul; 49(7):597-8. PubMed ID: 10923564
    [No Abstract]   [Full Text] [Related]  

  • 36. Diuretics: first choice for treating high BP.
    Health News; 2003 Feb; 9(2):8-9. PubMed ID: 12632547
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension.
    Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK
    JAMA; 2008 Jan; 299(3):296-307. PubMed ID: 18212314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Wright JT; Harris-Haywood S; Pressel S; Barzilay J; Baimbridge C; Bareis CJ; Basile JN; Black HR; Dart R; Gupta AK; Hamilton BP; Einhorn PT; Haywood LJ; Jafri SZ; Louis GT; Whelton PK; Scott CL; Simmons DL; Stanford C; Davis BR
    Arch Intern Med; 2008 Jan; 168(2):207-17. PubMed ID: 18227370
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT]).
    Alderman MH; Davis BR; Piller LB; Ford CE; Baraniuk MS; Pressel SL; Assadi MA; Einhorn PT; Haywood LJ; Ilamathi E; Oparil S; Retta TM;
    Am J Cardiol; 2016 Jan; 117(1):105-15. PubMed ID: 26589819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.